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For evidence‐based practice to succeed we need a body of evidence that is
large enough to o er precision, rigorous enough to inspire confidence, and
direct enough to equitably represent all social groups. Yet in too many areas
of clinical practice this remains an aspiration.
In their landmark overview of reviews, Eccleston and colleagues present us
with an arresting example of this problem.[1] Persistent pain in children is
common and results from a multitude of causes. It is responsible for
substantial su ering, disability, and costs to the child, their family, and to broader society.
Pharmacological interventions are o en first‐line approaches to pain treatment in children. If there are
pharmacological treatment options that o er a good chance of benefitting children and adolescents with
pain we need to know this so that we can o er those options with confidence. And if some of the options
that are available in adults are not e ective in children and adolescents or have an unfavourable safety
profile then we need to know so that we can minimize the risks that we expose them to. A clear and up‐
to‐date overview of the evidence for their e ectiveness is vital and timely.
We should find the results of this overview shocking. From 23 included systematic reviews across all
pharmacological agents there were just six randomized controlled trials (RCTs) that involved children
with chronic pain. Those RCTs provide only very low‐quality evidence for any given drug option. Not a
single trial was found in children with cancer‐related chronic pain.
Before we shrug at the familiar and disappointing mantras of ‘insu icient evidence’ and ‘more studies
are required’ it is useful to think more deeply about what these results mean, how this situation has
arisen, and what it might take to meet our aspirations of evidence‐based practice in paediatric persistent
pain. In their discussion, Eccleston and colleagues o er us food for thought.
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These findings reflect the uncomfortable truth that evidence‐based practice relating to drug options is
not currently possible for clinicians or for children in persistent pain and their families. In comparison to
the much more substantive and definitive evidence base available in adult care, the results point to a
lack of equity in the research culture of pain management, discriminating against children and
adolescents. They also highlight the considerable risks of suboptimal and unsafe pain management that
this population is exposed to, potentially in perpetuity.
Eccleston and colleagues outline how we might have arrived here. Research in children is clearly
challenging for a number of practical and ethical reasons, and recruiting large groups is o en not
possible. There is little market incentive for industry to invest and commit to large programmes of
research in this patient group, particularly for existing medicines. We have not yet seen the level of
sustained and substantial government or non‐industry funding that might be needed to make a
meaningful impact.
Expedience and the lack of a restrictive regulatory framework has facilitated the extrapolation of results
from trials in adults to the management of children and the common o ‐license use in children of drugs
licensed for adults. We should consider whether we are comfortable with that corner being cut. The
assumptions of equivalent e ectiveness and safety that underlie these practices are untested and have
been challenged.[2] Still, more and larger trials will only go so far in addressing the safety concerns that
this raises. There is currently little in the way of co‐ordinated infrastructure to allow for e ective
pharmacovigilance relating to analgesic use in children.
So to re‐use the bland cliché, more research is required. And urgently. The challenge is not
insurmountable. While by no means perfect, a more substantive evidence base exists to guide the drug
treatment of depression in children and adolescents.[3, 4] Judging by the rate of publications of new
trials seen in the chronic pain overview, the ball has not begun to roll.
Eccleston and colleagues highlight the need not just for more trials, but for research that seeks to better
understand the specific challenges of and barriers to producing quality evidence in paediatric pain. They
o er ideas for exploring innovative alternatives to traditional RCTs, such as single case designs. They
make the urgent case for national or trans‐national registries of children and adolescents treated for
chronic pain, with a primary focus on analgesic medicines.
Solving this problem may not require any great methodological innovations, just the will and resource to
do well what has not yet been done. There are almost no RCTs of analgesic medicines for children with
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